The direct mechanism by which TET2 loss contributes to lung cancer progression is unknown; however, TET2 is recognized as a tumor suppressor in non‐small‐cell lung cancer (NSCLC) [81]. Here, TET2 is linked to non-small cell lung carcinoma.